Sutent and Nexavar Put Brakes on Renal-Cell Carcinoma

January 10, 2007

NEW YORK -- Two drugs, Sutent (sunitinib) and Nexavar (sorafenib), slowed progression of advanced renal-cell carcinoma, investigators reported today, but it was not clear whether either agent would extend overall survival significantly.

NEW YORK, Jan. 10 -- Two drugs, Sutent (sunitinib) and Nexavar (sorafenib), slowed progression of advanced renal-cell carcinoma, investigators reported today, but it was not clear whether either agent would extend overall survival significantly.

Sutent more than doubled progression-free survival (P